Short-Term Adverse Effects Following Booster Dose of Inactivated-Virus vs. Adenoviral-Vector COVID-19 Vaccines in Algeria: A Cross-Sectional Study of the General Population

Mohamed Lounis, Hani Amir Aouissi, Samir Abdelhadi, Mohammed Amir Rais, Salem Belkessa and Djihad Bencherit

Abstract: COVID-19 booster vaccines have been adopted in almost all countries to enhance the immune response and combat the emergence of new variants. Algeria adopted this strategy in November 2021. This study was conducted to consider the self-reported side effects of COVID-19 booster vaccines by Algerians who were vaccinated with a booster dose of one of the approved inactivated-virus vaccines, such as BBIBP-CorV and CoronaVac, or one of the adenoviral-vector-based vaccines, such as Gam-COVID-Vac, AZD1222 and Ad26.COV2.S, and to determine the eventual risk factors. A cross-sectional study using an online self-administered questionnaire (SAQ) was conducted in Algeria between 28 April 2022, and 20 July 2022. A descriptive analysis of the 196 individuals who were included showed a nearly equal distribution of adenoviral- (52%) and inactivated-virus vaccines (48%) and of males (49.5%) and females (50.5%). The results showed that 74.7% of the studied population reported at least one local or systemic side effect. These side effects were more frequent among adenoviral-vector vaccinees (87.3%) than inactivated-virus vaccinees (60.6%) (sig. < 0.001). Injection site pain (40.3%), heat at the injection site (21.4%), and arm pain (16.3%) were the most common local side effects. These signs generally appeared in the first 12 h (73.3%) and generally lasted less than 24 h (32.8%). More interestingly, these signs differed from those that followed the administration of primer doses (48.5%) and were generally more severe (37%). The same observation was reported for systemic side effects, where the signs were especially most severe in the adenoviral-vaccinated group (49.4% vs. 20.8%; sig. = 0.001). These signs generally appeared within the first day (63.6%) and mostly disappeared before two days (50.8%), with fatigue (41.8%), fever (41.3%), and headache (30.1%) being the most common. Adenoviral-vector vaccinees (62.7%) were more likely to use medications to manage these side effects than were inactivated-virus vaccinees (45.7%) (sig. = 0.035) and paracetamol (48.5%) was the most used medication. Adenoviral-based vaccines were the types of vaccines that were most likely to cause side effects. In addition, being female increased the risk of developing side effects; regular medication was associated with local side effects among inactivated-virus vaccinees; and previous infection with COVID-19 was associated with systemic and local side effects among adenovirus-based vaccinees. These results support the short-term safety of booster vaccines, as has been reported for primer doses.

Keywords: COVID-19; vaccines; booster; side effects; adenoviral-vector vaccines; inactivated-virus vaccines; Algeria
1. Introduction

In late 2019, the world witnessed the emergence of one of the most noteworthy health threats of the 21st century, the COVID-19 pandemic [1]. As of 12 September 2022, the total number of infections worldwide was estimated to be more than 605 million and nearly 6.5 million deaths were recorded [2]. The disease has also had a range of disastrous effects on the economic sector, due to the preventive measures that were applied during the first months of the pandemic, which included border closings, social distancing, and quarantine [3,4].

Following multiple non-pharmaceutical measures, efforts were directed toward pharmaceutical measures by accelerating research trials to find the best vaccine for this disease. These efforts were concluded with the development of various types of vaccines in just one year [5]. In fact, six COVID-19 vaccines were urgently approved by the World Health Organization (WHO) in or after December 2020. Thus, a vaccination campaign race began in different countries. Later, other types of vaccines were also used in different countries. Currently, there are 11 vaccines approved by the WHO and, in at least one country, 47 vaccines have been approved [6]. These vaccines are of multiple types, including inactivated-virus, vector-based, protein-based, and mRNA-based vaccines [7].

The safety and effectiveness of the primer doses of these vaccines have been proved [8]. In fact, safety data about the two primer doses from previous studies showed that, as with any other drug, these vaccines could induce some short and mild adverse effects, including flu-like symptoms (e.g., headache, fatigue, and myalgia) and injection-site reactions [4,9–15]. Some severe signs, such as anaphylaxis, coagulation, myocarditis, thyroiditis, and even death, have also been reported, albeit rarely [16].

Regarding the efficacy of these vaccines, previous studies have confirmed that the vaccines are substantially associated with a decrease in hospitalization and death rates [4]. However, multiple studies have shown that, as with other vaccines, the efficacy of the COVID-19 vaccines decreases a few months after the second primer dose [17–19].

The waning protection of these vaccines, in association with the emergence of multiple variants of SARS-CoV-2 that were less sensitive than the first variants to these vaccines, has led several countries to recommend a booster dose for their populations, with either homologous or heterologous vaccines [16,20,21]. Consequently, the phenomenon of booster hesitancy/rejection emerged, although its frequency has not been as high as it was for primer doses.

In general, the phenomenon of vaccine hesitancy and rejection is mainly related to vaccines’ efficacy and safety. For instance, the effectiveness of boosters has been proven, in clinical trials and/or after their homologation, in the enhancement of immune responses, the control of infections, and the treatment of severe cases of the disease [21–24]. However, results regarding booster side effects are scarce.

In its vaccination campaign, Algeria approved five vaccines, including inactivated-virus vaccines (BBIBP-CorV and CoronaVac) and adenoviral-vector-based vaccines (Gam-COVID-Vac, AZD1222, and Ad26.COV2.S). The number of vaccinated people in Algeria with at least one dose since January 2021 has reached 7.84 million (17.75% of the total population), while the number of fully vaccinated people according to the initial protocol is estimated at 6.48 individuals (14.67% of the total population) [25]. The campaign for booster vaccination started in November 2021. However, despite the encouraging results regarding its acceptance, as reported in our previous study [26], the number of individuals who received a COVID-19 vaccine booster did not exceed 514,063, which represents approximately 1.3% of the total population [27].

Therefore, this study aimed to investigate the short-term side effects of the administration of the COVID-19 vaccine booster dose among the general population in Algeria and the associated risk factors. To the best of our knowledge, this is the first study conducted in Algeria about the side effects of COVID-19 vaccine boosters.
2. Materials and Methods

2.1. Study Design

The current cross-sectional study was conducted via a self-administered questionnaire (SAQ) with the aim of describing and evaluating the self-reported side effects of COVID-19 vaccines among Algerian people who have been vaccinated with a booster dose of one of the approved vaccines.

To achieve these objectives, the survey was carried out between 28 April 2022, and 20 July 2022. The designed SAQ was administered online, using Google Forms (Google LLC, Menlo Park, CA, USA, 2021). It was disseminated through social media platforms and emails, using uniform resource locator (URL), and a quick response (QR) was sought.

2.2. Participants

A convenient online sampling was used in the current study. The target population of this study was Algerian citizens living in Algeria who received a booster dose of one of the approved COVID-19 vaccines. Participants who received inactivated-virus or adenoviral-vector vaccines in their primers and booster doses were included. Participants who received other types of vaccines (i.e., other than inactivated-virus or adenoviral-vector vaccines) in their primer doses were excluded.

The minimum sample size was calculated using the following equation [28]:

\[ n = \frac{Z^2 pq}{e^2} \]

In the equation, \( n \): is the minimum sample size (here, \( n = 196 \));
\( Z^2 = 1.96 \) for \( \alpha = 0.05 \) (confidence interval of 95%);
\( p \) is the proportion (\( p = 0.5 \); in the 2022 study of Lounis et al. [14], approximately 50% of the vaccinated population developed at least one local or systemic side effect);
\( q = 1 - p \); and
\( e \) is the accepted margin of error (ME) (here, we chose an ME of 7%, or 0.07);

In total, 208 responses were received in this study. However, only 196 participants were included for further analyses. Participation in the survey was voluntary and there were no incentives or compensation. No identity data were requested from the participants and anonymity was ensured to control Hawthorne’s effect and information bias.

2.3. Instrument

The SAQ utilized in this study was obtained and adapted from previous studies regarding COVID-19 primer and booster doses [9–15,20,21]. The questionnaire was translated and distributed in both Arabic and French languages.

In this SAQ, 40 multiple-choice items were used, which were grouped into three categories: (i) demographic features that included sex, age, and professional status; (ii) anamnestic features, including chronic diseases, BMI, ABO group, regular used medications, allergies, smoking status, previous COVID-19 infection, COVID-19 vaccine primer and booster type, the duration between primer and booster doses, and the participant’s state of mind during vaccination; and (iii) post-vaccination local and systemic side effects, their onset and duration, post-vaccination-used medications, and hospitalization.

2.4. Ethical Considerations

This study protocol was reviewed and approved by the Scientific Committee of the Faculty of Natural and Life Sciences, University of Djelfa, on 25 April 2022. (It was signed by the president of the scientific committee and the dean of the faculty).

Electronic informed consent was obtained from all participants before their enrolment in the study. Participants could not continue the survey if they declined consent. They could leave the survey at any time, in accordance with the Declaration of Helsinki’s ethical principles.
2.5. Statistical Analysis

Data were statistically analyzed utilizing SPSS version 22.0 (SPSS Inc., Chicago, IL, USA, 2013). Data were presented as frequencies (n) and percentages (%) to summarize nominal and ordinal data. The association between independent and dependent variables was evaluated using Chi-squared (χ²) and Fisher tests.

Subsequently, multinomial logistic regression was used to evaluate the suggested risk factors of post-vaccination side effects following boosters with either of the two types of vaccines. All data were analyzed with a confidence level (CI) of 95% and a significance level (sig.) of ≤ 0.05.

3. Results

3.1. Demographic and Anamnestic Characteristics of the Study Population

In the current study, 208 individuals vaccinated with one of the approved vaccines (adenoviral vaccines or inactivated-virus vaccines) and receiving a booster dose from different regions of Algeria completed the questionnaire during the study period from 28 April 2022, to 20 July 2022.

Due to incomplete responses or other reasons (i.e., individuals who received different types of vaccines in their primer doses), 12 questionnaires were excluded. A total of 196 responses were included in this study.

Demographic characteristics showed that the participants were nearly equally distributed in terms of sex (male, n = 97 vs. female, n = 99). With respect to age, the most reported categories were for those participants who were aged between 18 and 30 years (65, 33.2%) and between 31 and 40 years (n = 55, 28.2%). For BMI, weight, and blood group, the figures were as follows: normal BMI (n = 92, 46.9%); overweight (n = 73, 37.8%); O blood group (n = 80, 40.8%).

Regarding health status, most of the respondents (n = 164, 83.7%) were non-smokers and 37.2% (n = 73) suffered from an allergy.

Further, forty-four of the participants (22.4%) suffered from at least one chronic disease, with hypertension (9.2%, n = 18), diabetes (8.2%, n = 16), and respiratory diseases (4.1%, n = 8) as the most common. Regarding regular medication, 15.3% of the participants (n = 30) were taking antihistamines and 13.8% (n = 27) used antibiotics regularly (Table 1).

Table 1. Demographic and anamnestic characteristics of the study population.

| Variable          | Adenoviral-Virus Vaccines (n = 102) | Inactivated-Virus Vaccines (n = 94) | Total (n = 196) |
|-------------------|------------------------------------|------------------------------------|-----------------|
| **Age**           |                                    |                                    |                 |
| 18–30 years old   | 30 (29.4)                          | 35 (37.2)                          | 65 (33.2)       |
| 31–40 years old   | 29 (28.4)                          | 25 (26.6)                          | 54 (27.6)       |
| 41–50 years old   | 22 (21.6)                          | 20 (21.3)                          | 42 (21.4)       |
| Over 50 years old | 21 (20.6)                          | 14 (14.9)                          | 35 (17.9)       |
| **Sex**           |                                    |                                    |                 |
| Male              | 48 (47.1)                          | 49 (52.1)                          | 97 (49.5)       |
| Female            | 54 (52.9)                          | 45 (47.9)                          | 99 (50.5)       |
| **ABO group**     |                                    |                                    |                 |
| A                 | 30 (29.4)                          | 30 (31.9)                          | 60 (30.6)       |
| B                 | 13 (12.7)                           | 3 (3.2)                            | 16 (8.2)        |
| AB                | 19 (18.6)                           | 19 (20.2)                          | 38 (19.4)       |
| O                 | 39 (38.2)                           | 41 (43.6)                          | 80 (40.8)       |
| **BMI**           |                                    |                                    |                 |
| Normal            | 45 (44.1)                          | 47 (50)                            | 92 (46.9)       |
| Obese             | 38 (37.3)                           | 35 (37.2)                          | 73 (37.2)       |
| Over Obese        | 19 (18.6)                           | 12 (12.8)                          | 31 (15.8)       |
| **Allergy**       |                                    |                                    |                 |
| (Yes)             | 38 (37.3)                          | 35 (37.2)                          | 73 (37.2)       |
| **Smokers**       |                                    |                                    |                 |
| (Yes)             | 13 (12.7)                           | 19 (20.2)                          | 32 (16.3)       |
Table 1. Cont.

| Variable                  | Adenoviral-Virus Vaccines (n = 102) | Inactivated-Virus Vaccines (n = 94) | Total (n = 196) |
|---------------------------|-------------------------------------|-------------------------------------|-----------------|
|                           | Number (%)                          | Number (%)                          | Number (%)      |
| Chronic diseases (Yes)    | 28 (27.5)                           | 16 (17)                             | 44 (22.4)       |
| Hypertension              | 9 (8.8)                             | 9 (9.6)                             | 18 (9.2)        |
| Diabetis                  | 10 (9.8)                            | 6 (6.4)                             | 16 (8.2)        |
| COPD                      | 6 (5.9)                             | 2 (2.1)                             | 8 (4.1)         |
| Cardiovascular            | 2 (2)                               | 2 (2.1)                             | 4 (2.0)         |
| Thyroid                   | 4 (3.9)                             | 0 (0)                               | 4 (2.0)         |
| Others                    | 5 (4.9)                             | 6 (6.4)                             | 11 (5.6)        |
| Medication (Yes)          | 58 (56.9)                           | 38 (40.4)                           | 96 (49)         |
| Antihistamines            | 19 (18.6)                           | 11 (11.7)                           | 30 (15.3)       |
| Antibiotics               | 17 (16.7)                           | 10 (10.6)                           | 27 (13.8)       |
| Antihypertensive          | 8 (7.8)                             | 9 (9.6)                             | 17 (8.7)        |
| Anti-reflux               | 9 (8.8)                             | 5 (5.3)                             | 14 (7.1)        |
| Anti-diabetes             | 7 (6.9)                             | 5 (5.3)                             | 12 (6.1)        |
| Anti-sthma                | 8 (7.8)                             | 3 (3.2)                             | 10 (5.1)        |
| Contraceptives            | 6 (5.9)                             | 2 (2.1)                             | 8 (4.1)         |
| Antidepressants           | 3 (2.9)                             | 4 (4.3)                             | 7 (3.6)         |
| Thyroid hormones          | 4 (3.9)                             | 3 (3.2)                             | 7 (3.6)         |
| Corticoids                | 3 (2.9)                             | 4 (4.3)                             | 7 (3.6)         |
| Cholesterol lowering      | 3 (2.9)                             | 1 (1.1)                             | 4 (2)           |
| Anticoagulant             | 1 (1)                               | 1 (1.1)                             | 2 (1)           |

3.2. COVID-19 Infection History and Vaccine Primer and Booster Characteristics

Concerning COVID-19 history, the majority of the respondents (71.9%, n = 141) had contracted the disease, and most of them were infected one time (80.1%, n = 113) and infected generally before primer vaccination (86.5%, n = 122).

For the primer doses of vaccination, vaccines were distributed among inactivated-virus (60.7%, n = 117) and adenoviral-vector-based (39.3%, n = 77) vaccines, with Sinovac and AstraZeneca as the most represented, respectively.

On the other hand, the adenoviral-vector-based (52%, n = 102) vaccines were used more for a booster dose than were inactivated-virus vaccines (48%, n = 94); the Janssen vaccine was the most used among the first type.

Most of the participants were vaccinated (71.4%, n = 140) more than 3 months before the survey, and the duration between the second primer and the booster doses was generally between 3 and 6 months (46.9%, n = 92).

Overall, 43.3% (n = 85) and 40.3% (n = 79) of the participants declared that they were serene or indifferent just before the booster vaccination, while 9.2% (n = 18) and 6.1% (n = 12) were worried or anxious, respectively (Table 2).

Table 2. COVID-19 infection history and booster uptake of the studied population.

| Variable                | Number | Frequency (%) |
|-------------------------|--------|---------------|
| COVID-19 infection      |        |               |
| No                      | 55     | 28.1          |
| Yes                     | 141    | 71.9          |
| Number of infections    |        |               |
| One time                | 113    | 80.1          |
| Two times               | 23     | 16.3          |
| Three times             | 4      | 2.8           |
| Onset                   |        |               |
| Before vaccination      | 122    | 86.5          |
| After the first dose    | 19     | 13.5          |
| After the second dose   | 35     | 24.8          |
| After the third dose    | 27     | 19.1          |
Table 2. Cont.

| Variable                           | Number | Frequency (%) |
|------------------------------------|--------|---------------|
| **Vaccination timing**             |        |               |
| From a month to 3 months ago       | 39     | 19.9          |
| From a week to one month ago       | 12     | 6.1           |
| Less than a week ago               | 5      | 2.6           |
| More than 3 months ago             | 140    | 71.4          |
| **Vaccine first dose**             |        |               |
| AstraZeneca (ChAdOx1, AZD1222)     | 37     | 18.9          |
| Janssen (Ad26.CoV2.S)              | 5      | 2.6           |
| Sinopharm (BBIBP-CoV)              | 20     | 10.2          |
| Sinovac (CoronaVac)                | 99     | 50.5          |
| Sputnik V (Gam-COVID-Vac)          | 35     | 17.9          |
| **Vaccine second dose**            |        |               |
| AstraZeneca (ChAdOx1, AZD1222)     | 36     | 18.4          |
| Janssen (Ad26.CoV2.S)              | 5      | 2.6           |
| Sinopharm (BBIBP-CoV)              | 23     | 11.7          |
| Sinovac (CoronaVac)                | 96     | 49.0          |
| Sputnik V (Gam-COVID-Vac)          | 36     | 18.4          |
| **Vaccine booster**                |        |               |
| AstraZeneca (ChAdOx1, AZD1222)     | 28     | 14.3          |
| Janssen (Ad26.CoV2.S)              | 71     | 36.2          |
| Sinopharm (BBIBP-CoV)              | 13     | 6.6           |
| Sinovac (CoronaVac)                | 81     | 41.3          |
| Sputnik V (Gam-COVID-Vac)          | 3      | 1.5           |
| **Primer doses type**              |        |               |
| Adenoviral-vector virus            | 77     | 39.3          |
| Inactivated virus                  | 119    | 60.7          |
| **Booster dose type**              |        |               |
| Adenoviral-vector virus            | 102    | 52.0          |
| Inactivated virus                  | 94     | 48.0          |
| **Time between primer and booster doses (months)** | | |
| 1 month                            | 19     | 9.7           |
| 1 to 3 months                      | 33     | 16.8          |
| 3 to 6 months                      | 92     | 46.9          |
| More than 6 months                 | 51     | 26.0          |
| **State of mind during booster vaccination** | | |
| Anxious                            | 12     | 6.1           |
| Worried                            | 18     | 9.2           |
| Indifferent                        | 79     | 40.3          |
| Serene                             | 85     | 43.4          |

3.3. Booster Side Effects

Based on our results, 146 individuals (74.7%) reported at least a local or a systemic side effect, with a significant difference between the adenoviral-vector vaccine group (87.3%) and the inactivated-virus vaccine group (60.6%) (sig. < 0.001). In addition, 123 (62.8%) and 125 (63.8%) individuals developed at least one local or systemic side effect, respectively, with a statistical difference between the adenoviral-based vaccines and the inactivated-based vaccines.

3.3.1. Local Side Effects

Our results showed that the most commonly reported local side effects were injection-site pain (40.3%, n = 79), heat at the injection site (21.4%, n = 42), and arm pain (16.3%, n = 32). Redness (12.8%, n = 25), injection-site itching and indurations (8.7%, n = 17), and swelling (6.1%, n = 12) were also reported (Figure 1).
Figure 1. Frequency of local side effects reported by the studied population.

These signs generally appeared generally in the first 12 h (73.7%) and generally lasted less than 24 h (32.8%) or between 24 and 72 h (36.1%). In addition, nearly half of the respondents (48.5%) declared that these signs differed from those of the primer doses; 37% of the respondents declared that these signs were more severe than those that appeared during the primer doses. No statistically significant difference was reported between the two types of vaccines (Table 3).

Table 3. Frequency and characteristics of local side effects of the Algerian population.

| Variable                              | Booster Vaccine Type                  | Sig.   |
|---------------------------------------|--------------------------------------|--------|
|                                       | Adenoviral-Vector-Virus | Inactivated-Virus | Total |  |        |
| Local side effects                    |                                      |        |
| Injection-site pain                   | 54 (52.9)                           | 25 (26.6) | 70 (40.3) | 0.000 |
| Arm pain                              | 20 (19.6)                           | 12 (12.8) | 32 (16.3) | 0.195 |
| Heat at the injection site            | 26 (25.5)                           | 16 (17)   | 42 (21.4) | 0.149 |
| Injection-site itching and induration| 11 (10.8)                           | 6 (6.4)   | 17 (8.7)  | 0.274* |
| Redness                               | 18 (17.6)                           | 7 (7.4)   | 25 (12.8) | 0.032 |
| Swelling                              | 10 (9.8)                            | 3 (2.1)   | 12 (6.1)  | 0.052* |
| Onset                                 |                                      |        |
| <12 h                                 | 58 (75.3)                           | 29 (70.7) | 87 (73.7) | 0.589 |
| >12 h                                 | 10 (13)                             | 10 (24.4) | 20 (16.9) | 0.129* |
| >24 h                                 | 9 (11.7)                            | 2 (4.9)   | 11 (9.3)  | 0.327* |
| Duration                              |                                      |        |
| Less than 24 h                        | 27 (34.2)                           | 12 (30)   | 39 (32.8) | 0.647 |
| From 24 to 72 h                       | 30 (38)                             | 13 (32.5) | 43 (36.1) | 0.557 |
| From 3 days to a week                 | 15 (19)                             | 7 (17.5)  | 22 (18.5) | 1*    |
| More than a week                      | 7 (8.9)                             | 8 (20)    | 15 (12.6) | 0.141* |
| Similarity                            |                                      |        |
| Not the same signs                    | 45 (53.6)                           | 21 (40.4) | 66 (48.5) | 0.135 |
| The same signs as the first dose      | 19 (22.6)                           | 15 (28.8) | 34 (25)   | 0.415 |
| The same signs as the second dose     | 2 (2.4)                             | 5 (9.6)   | 7 (5.1)   | 0.106* |
| The same signs as the two primer doses| 19 (21.4)                           | 11 (21.2) | 29 (21.3) | 0.970 |
| Severity                              |                                      |        |
| The same severity as the two primer doses | 20 (25.6)             | 19 (38.8) | 39 (30.7) | 0.118 |
| Less severe than the two primer doses | 24 (30.8)                           | 17 (34.7) | 41 (32.3) | 0.645 |
| More severe than the two primer doses | 34 (43.6)                           | 13 (26.5) | 47 (37)   | 0.052 |

Chi-squared ($\chi^2$) and Fisher (*) tests were used with a significance level (sig.) of 0.05. Bold character refers to statistically significant values.
3.3.2. Systemic Side Effects

With regard to systemic side effects, the most common reported signs were fatigue (41.8%, n = 82), fever (41.3%, n = 81), and headache (30.1%, n = 59). Fatigue and fever in association with chills and arthralgia (which were reported among 21.9% and 21.4% of the respondents, respectively) were significantly more frequent among adenovirus vaccines than inactivated-virus vaccines. Dizziness (17.9%, n = 35) and sweating (17.3%, n = 34) were also frequent, while other signs, including somnolence, cough, insomnia, dyspnea, nasal discharge, chest pain, abdominal pain, diarrhea, loss of taste/smell, halitosis, and myalgia, were reported with low frequencies varying from 0.5 to 9.2%. Their frequencies were not statistically different among the two vaccinated groups (Figure 2).

Regarding the onset of systemic side effects, most of them appeared within the first day (63.6%), with no difference between the two groups. Systemic side effects appeared more quickly in inactivated-virus vaccinee group than in the adenovirus-based vaccinee group.

Regarding the duration of systemic side effects, they mostly disappeared within two days (50.8%) or between two days and one week (28.3%), with no statistically significant difference between the two groups. These signs were different from those reported during the primer dose vaccination (48.6%), an observation that was significantly more frequent for the adenoviral-vaccinated group (56%) than for the inactivated-virus group (37%) (sig. = 0.032). Regarding the severity of systemic side effects, they were generally more severe than the effects of the primer dose for the adenoviral-vaccinated group (49.4% vs. 20.8%; sig. = 0.001) and less severe than those of the primer dose for the inactivated-vaccine group (41.7% vs. 26%, sig. = 0.003) (Table 4).

Regarding the participants’ ways of managing these post-vaccination adverse effects, more than half (54.6%, n = 107) reported that they used medication after vaccination. Medications were more frequently used by adenoviral-vector vaccinees (62.7%, n = 62) than by inactivated-virus vaccinees (45.7%, n = 43) (sig. = 0.035). Paracetamol (48.5%), poly-vitamins (21.4%, n = 42), and herbal traditional infusions (19.4%, n = 36) were the most used medications. In addition, 36 individuals declared that they were absent from work after vaccination (mostly those among the adenoviral-vector vaccinees (69.44%, n = 25)) for a period varying from 1 to 32 days, while only one person who received inactivated-virus vaccine required hospitalization.
Table 4. Frequency and characteristics of systemic side effects of the Algerian population.

| Variable         | Outcomes                      | Booster Vaccine Type | Sig.  |
|------------------|-------------------------------|----------------------|-------|
|                  | Adenoviral-Vector Virus       | Inactivated Virus    | Total |       |
| Fever            | 54 (52.9)                     | 27 (28.7)            | 81 (41.3) | 0.001 |
| Fatigue          | 51 (50)                       | 31 (33)              | 82 (41.8) | 0.016 |
| Headache         | 34 (33.3)                     | 25 (26.6)            | 59 (30.1) | 0.304 |
| Chills           | 32 (31.4)                     | 11 (11.7)            | 43 (21.9) | 0.001 |
| Arthralgia       | 30 (29.4)                     | 12 (12.8)            | 42 (21.4) | 0.005 |
| Dizziness        | 22 (21.6)                     | 13 (13.8)            | 35 (17.9) | 0.158 |
| Sweating         | 12 (11.8)                     | 6 (6.4)              | 18 (9.2) | 0.223* |
| Systemic side effects |                           |                      |       |
| Cough            | 10 (9.8)                      | 4 (4.3)              | 14 (7.1) | 0.169* |
| Insomnia         | 10 (9.8)                      | 7 (7.4)              | 17 (8.7) | 0.619* |
| Dyspnea          | 8 (7.8)                       | 2 (2.1)              | 10 (5.1) | 0.103* |
| Nasal discharge  | 6 (6.9)                       | 4 (4.3)              | 11 (5.6) | 0.541* |
| Chest pain       | 6 (5.9)                       | 2 (2.1)              | 8 (4.1) | 0.282* |
| Abdominal pain   | 6 (5.9)                       | 2 (2.1)              | 8 (4.1) | 0.282* |
| Diarrhea         | 7 (6.9)                       | 4 (4.3)              | 11 (6.2) | 0.604* |
| Loss of taste/smell | 6 (5.9)                 | 4 (4.3)              | 10 (5.1) | 0.75* |
| Halitosis        | 7 (6.9)                       | 2 (2.1)              | 9 (4.6) | 0.173* |
| Myalgia          | 1 (1)                         | 0 (0)                | 0 (0.5) | 1*     |

Onset

|                | Immediately | The first day | The first week | The second week | After the first month |
|----------------|-------------|---------------|----------------|-----------------|----------------------|
| Less than 2 days | 41 (54.7)   | 20 (44.4)     | 61 (50.8)      | 0.278           |
| From 2 days to a week | 18 (24)     | 16 (35.6)     | 34 (28.3)      | 0.174           |
| From a week to 2 weeks | 7 (9.3)     | 2 (4.4)       | 9 (7.5)        | 0.481*           |
| From 2 weeks to 4 weeks | 2 (2.7)     | 1 (2.2)       | 3 (2.5)        | 1*               |
| More than 4 weeks | 7 (9.3)     | 6 (13.3)      | 13 (10.8)      | 0.551*           |

Duration

|                             | Not the same signs | The same as the first dose | The same as the second dose | The same as the primer doses |
|-----------------------------|--------------------|----------------------------|-----------------------------|-----------------------------|
| Less than 2 days            | 47 (56)            | 21 (37.5)                  | 68 (48.6)                   | 0.032                       |
| From 2 days to a week       | 21 (25)            | 18 (32.1)                  | 39 (27.9)                   | 0.356                       |
| From a week to 2 weeks      | 3 (3.6)            | 7 (12.5)                   | 10 (7.1)                    | 0.089*                      |
| From 2 weeks to 4 weeks     | 13 (15.5)          | 10 (17.9)                  | 23 (16.4)                   | 0.817*                      |
| More than 4 weeks           | 7 (9.3)            | 6 (13.3)                   | 13 (10.8)                   | 0.551*                      |

Similarity

|                             | The same severity as the primer doses | Less severe than the primer doses | More severe than the primer doses |
|-----------------------------|--------------------------------------|-----------------------------------|----------------------------------|
| Less than 2 days            | 19 (24.7)                            | 20 (26)                           | 38 (49.4)                        |
| From 2 days to a week       | 18 (37.5)                            | 20 (41.7)                         | 10 (20.8)                        |
| From a week to 2 weeks      | 37 (29.6)                            | 40 (32)                           | 48 (38.4)                        |

Severity

Chi-squared ($\chi^2$) and Fisher (*) tests were used with a significance level (sig.) of 0.05. Bold character refers to statistically significant values.

3.4. Risk Factors of the Side Effects of Vaccines

In the current study, multiple factors were associated with local and/or systemic side effects. Being female was highly associated with side effects (81.8% vs. 67%) for both local (70.7% vs. 54.6%) and systemic side effects (73.7% vs. 53.6%). In addition, individuals aged more than 50 years (77.1%) and obese persons (80.6%) were more exposed to systemic side effects than were their counterparts, while persons with normal BMI were most significantly associated with a low frequency of any side effects. In contrast, individuals suffering from chronic illnesses were significantly associated with systemic and local side effects (88.6%) and only systemic side effects (77.3%), but not with local side effects. On the other hand, taking medication regularly was significantly associated with local side effects (77.1%) or local and systemic side effects (83.3%), but not with systemic side effects alone.

Another highly associated factor with all side effects (87.3% vs. 60.6%), local side effects (75.5% vs. 51.1%) and systemic side effects (77.5% vs. 46.8%) was the use of the adenoviral-based vaccines, compared with the inactivated-virus vaccines. In addition, the use of adenovirus-based vaccines in primer–booster doses was associated with high...
frequencies of total, local, and systemic side effects, while the use of inactivated-virus vaccines was associated with the lowest frequencies.

In this study, local and/or systemic side effects were not statistically associated with ABO groups, allergy, smoking, or previous COVID-19 infections (Table 5).

Table 5. Risk factors associated with side effects in the Algerian population.

| Variable                    | Local Side Effects | Systemic Side Effects | Total Side Effects |
|-----------------------------|-------------------|-----------------------|-------------------|
|                             | Number (%)        | Sig.                  | Number (%)        | Sig.                  | Number (%) | Sig.                  |
| Age                         |                   |                       |                   |                       |            |                       |
| 18–30 years old             | 39 (60)           | 0.574                 | 37 (56.9)         | 0.160                 | 44 (67.7)  | 0.124                 |
| 31–40 years old             | 32 (59.3)         | 0.532                 | 36 (66.7)         | 0.604                 | 39 (72.2)  | 0.653                 |
| 41–50 years old             | 29 (69)           | 0.341                 | 25 (59.5)         | 0.518                 | 32 (76.2)  | 0.775                 |
| Over 50 years old           | 23 (65.7)         | 0.689                 | 27 (77.1)         | **0.036**             | 31 (88.6)  | 0.114                 |
| Sex                         |                   |                       |                   |                       |            |                       |
| Male                        | 53 (54.6)         | **0.02**              | 52 (53.6)         | **0.003**             | 65 (67)    | **0.017**             |
| Female                      | 70 (70.7)         |                       | 73 (73.7)         |                       | 81 (81.8)  |                       |
| ABO group                   |                   |                       |                   |                       |            |                       |
| A                           | 37 (61.7)         | 0.703                 | 40 (66.7)         | 0.528                 | 45 (75)    | 0.869                 |
| AB                          | 10 (62.5)         | 1                     | 10 (62.5)         | 1                     | 11 (68.8)  | 0.563                 |
| B                           | 27 (71.1)         | 0.245                 | 27 (71.1)         | 0.275                 | 31 (81.6)  | 0.304                 |
| O                           | 48 (60)           | 0.486                 | 46 (57.5)         | 0.153                 | 57 (71.3)  | 0.427                 |
| BMI class                   |                   |                       |                   |                       |            |                       |
| Normal                      | 52 (56.5)         | 0.090                 | 54 (58.7)         | 0.164                 | 61 (66.3)  | 0.013                 |
| Obese                       | 47 (64.4)         | 0.716                 | 46 (63)           | 0.864                 | 58 (79.5)  | 0.220                 |
| Overly obese                | 24 (77.4)         | 0.072                 | 25 (80.6)         | **0.041**             | 27 (87.1)  | 0.114                 |
| Chronic diseases            |                   |                       |                   |                       |            |                       |
| Yes                         | 32 (72.7)         | 0.12                  | 34 (77.3)         | **0.034**             | 39 (88.6)  | 0.015                 |
| No                          | 91 (59.9)         |                       | 91 (59.9)         |                       | 107 (70.4) |                       |
| Allergy                     |                   |                       |                   |                       |            |                       |
| Yes                         | 49 (67.1)         | 0.33                  | 50 (68.5)         | 0.290                 | 57 (78.1)  | 0.374                 |
| No                          | 74 (60.2)         |                       | 75 (61)           |                       | 89 (72.4)  |                       |
| Smoking                     |                   |                       |                   |                       |            |                       |
| Yes                         | 19 (59.4)         | 0.665                 | 18 (56.3)         | 0.333                 | 21 (65.6)  | 0.374                 |
| No                          | 104 (63.4)        |                       | 107 (65.2)        |                       | 125 (76.2) |                       |
| Medication                  |                   |                       |                   |                       |            |                       |
| Yes                         | 74 (77.1)         | **0.000**             | 67 (69.8)         | 0.086                 | 80 (83.3)  | 0.005                 |
| No                          | 49 (49)           |                       | 58 (58)           |                       | 66 (66)    |                       |
| COVID-19 infection          |                   |                       |                   |                       |            |                       |
| Yes                         | 71 (58.7)         | 0.134                 | 77 (63.6)         | 0.959                 | 88 (73.8)  | 0.707                 |
| No                          | 52 (69.3)         |                       | 48 (64)           |                       | 58 (76.4)  |                       |
| Booster type                |                   |                       |                   |                       |            |                       |
| Adenoviral-virus            | 79 (77.5)         | **0.000**             | 77 (75.5)         | **0.000**             | 89 (87.3)  | **0.000**             |
| Inactivated-virus           | 44 (46.8)         |                       | 48 (51.1)         |                       | 57 (60.6)  |                       |
| Mixing/matching             |                   |                       |                   |                       |            |                       |
| (primers-booster)           |                   |                       |                   |                       |            |                       |
| AA +                        | 43 (79.6)         | **0.003**             | 40 (74.1)         | **0.064**             | 50 (92.6)  | **0.000**             |
| AI +                        | 11 (47.8)         | 0.115                 | 11 (47.8)         | 0.09                  | 13 (56.5)  | **0.035**             |
| IA +                        | 38 (74.5)         | **0.044**             | 39 (76.5)         | **0.028**             | 40 (81.6)  | 0.256                 |
| II +                        | 31 (45.6)         | **0.000**             | 35 (51.5)         | **0.009**             | 43 (61.4)  | **0.002**             |
| Time between primers and    |                   |                       |                   |                       |            |                       |
| booster doses (months)      |                   |                       |                   |                       |            |                       |
| 1 month or less             | 11 (57.9)         | 0.619                 | 12 (63.2)         | 1.000                 | 14 (73.7)  | 1                     |
| 1 to 3 months               | 19 (57.6)         | 0.472                 | 19 (57.6)         | 0.431                 | 21 (63.6)  | 0.122                 |
| 3 to 6 months               | 64 (69.6)         | 0.076                 | 62 (67.4)         | 0.297                 | 74 (80.4)  | **0.066**             |
| More than 6 mths            | 29 (56.9)         | 0.285                 | 31 (60.8)         | 0.628                 | 36 (70.6)  | 0.473                 |

Chi-squared ($\chi^2$) test was used with a significance level (sig.) of 0.05. Bold character refers to statistically significant values. * A: adenoviral-based vaccine, I: inactivated-virus vaccine.

The results of the logistic multinomial regression showed that one of the most determinant factors for developing side effects is the type of vaccine. In fact, the adenoviral-based vaccines are highly associated with the emergence of side effects (OR: 4.520, CI 95%: 2.017–10.127), either for local (OR: 3.648, CI 95%: 1.832–7.266) or systemic side effects (OR: 2.995, CI 95%: 1.517–5.911). In addition, being female is a determinant factor in developing side effects (OR: 2.714, CI 95%: 1.179–6.25), either for local (OR: 2.17, CI 95%: 1.027–4.585) or systemic side effects (OR: 2.956, CI 95%: 1.416–6.173). In addition, taking medication was associated with the presence of local side effects, especially among inactivated-virus vaccinees (OR: 6.37, CI 95%: 1.96–20.833), while previous infection with COVID-19 was
associated with systemic and local side effects (OR: 5.983, CI 95%: 1.009–35.5), especially for adenovirus-based vaccinees (OR: 6.369, CI: 1.432–28.336).

4. Discussion

The current study aimed to determine the self-reported adverse effects and possible associated risk factors among Algerian people who receive a booster dose of approved vaccines. These side effects were compared between adenoviral-based vaccinees and inactivated-virus vaccinees. In fact, describing the side effects of booster vaccines could help to confirm the safety of these vaccines and, therefore, help to reduce the phenomenon of vaccine (booster) hesitancy, which is a phenomenon described for both primer and booster doses of COVID-19 in Algeria [26,29] and around the world [30,31]. Only limited data are available around the world about the side effects of boosters [16,20,32–36]. Moreover, little is known about the frequency of these side effects in Algeria.

In this study, 74.7% of the surveyed population reported at least a local or a systemic side effect. These results concurred with those of Nguyen et al. [16], who reported at least one side effect in 79.1% of the Vietnamese population after the booster dose. Additionally, in our study, 62.8% and 63.8% of the respondents developed at least one local or systemic side effect, respectively. These side effects were more frequent in adenoviral-vector vaccinees (87.3%) than in inactivated-virus vaccinees (60.6%). These findings confirm the previous reports of multiple studies that reported that side effects were less frequent for inactivated-virus vaccines than for the other types (adenoviral-based vaccines and mRNA-based vaccines) after both primer doses [14,16] and booster doses [35,36].

In this work, nearly half of the participants (48.5%) declared that the side effects they developed after the booster dose were different, and generally more severe (37.7%), than those that developed after the primer doses. This finding was particularly observed by individuals who received adenoviral-based vaccines, and more specifically by those who were vaccinated with inactivated-virus vaccines for their primer doses (i.e., those who mixed inactivated-virus and adenoviral-based vaccines in the primer–booster doses, respectively); nearly three quarters of the respondents (73.7%) declared that systemic side effects were more severe after the booster dose. Moreover, half of those respondents who mixed adenoviral-based and inactivated-virus (primer–booster) vaccines, respectively, declared that the side effects were less severe. These results confirmed the severity of the side effects of adenoviral-based vaccines, compared with inactivated-virus vaccines, as reported in our previous study on primer doses in Algeria [14]. However, these signs remain manageable and generally disappear after a few days.

On the other hand, recently, Chansaenroj et al. [32] reported that the side effects that follow mixed inactivated-viral vector and inactivated-mRNA (primer–booster) doses are generally mild. They confirmed that the reactogenicity after this protocol was acceptable. Other heterologous programs were also shown to induce a greater immune response than that of the homologous protocol [37]. Similarly, the results of multiple studies reported that side effects were the same or milder after the booster dose, compared with the primer doses [16,38–40]. However, Rzymski et al. [20] reported that individuals who developed more side effects after the primer doses were more likely to develop side effects after the booster dose. They explained these findings by differences in individual reactions and by the nocebo phenomenon related to anxiety that is associated with misconceptions about potential side effects [20]. In our study, the participants’ states of mind during vaccination were not associated with the appearance of side effects.

Our results showed that injection-site pain (40.3%), heat at the injection site (21.4%), and arm pain (16.3%) were the most common local side effects, while the most frequent systemic side effects were fatigue (41.8%), fever (41.3%), and headache (30.1%). These side effects were generally more frequent in the adenoviral-based vaccinated group than in the inactivated-virus vaccinated group. These results accord with the available findings about booster side effects [16,33–37], with some differences in their frequencies. These side effects were also common after primer doses [9–15]. They are, however, reported
with higher frequency by healthcare workers than were reported after the primer dose, as noted in our previous study [14]. These side effects disappeared quickly and were generally manageable. In fact, only one individual was hospitalized, while 54.6% used medication, and paracetamol was the most used (48.5%). This approach is common, as reported in previous studies [14,15,20]. In this way, previous studies about COVID-19 and other vaccines (such as hepatitis vaccine) reported that the use of paracetamol is safe and did not affect the immune reaction [41,42]. Consequently, this drug has been recommended by some health authorities to relieve the adverse effects of COVID-19 vaccines [43].

Regarding risk factors associated with the development of side effects, our study showed that females, individuals taking regular medications, and those respondents with previous COVID-19 infections were the most exposed to developing local or systemic side effects. The predisposition of females to the side effects of vaccines was previously documented for both primer and booster doses [14,20,36], regardless of the type of vaccine. The explanation of this phenomenon is related to the behavioral, hormonal, and genetic differences between males and females that lead to different immunological reactions [44]. Based on COVID-19 history, the increasing of side effects could be related to the higher antibody titer after the vaccination of individuals who had past contact with SARS-CoV-2 [14]. The disparate results in multiple studies on multiple vaccines could, however, be related to the fact that the period between COVID-19 infection and vaccination has rarely been determined, which was the case in our study.

In this study, a statistically significant relationship was observed between previous use of medication and local side effects (OR: 3.41, CI 95%: 1.55–7.46). These results, however, need to be interpreted with some caution, due to the various types of medications used and their various mechanisms of action.

Surprisingly, in our study, age, chronic diseases, and BMI were not associated with the development of side effects. In fact, elderly individuals and those with chronic diseases and high BMI are known to be characterized by weak immune-system reactions, confirming previous results of multiple studies that reported that people in these categories developed adverse effects less frequently than those in other age groups [45–48].

4.1. Limitations

Our study had some limitations that could affect our results. The main limitation was the low number of participants, which was related to the low number of individuals who receive vaccine booster doses in Algeria. A second limitation is that the period of study coincided with the return to the “new normal life” and, accordingly, people are generally tending to disregard subjects related to the COVID-19 pandemic. Another limitation was related to the online nature of this survey and the convenient sampling method, which made it difficult to state generalizations about the results. Nevertheless, this method had its benefits, as it mainly covered all regions of Algeria and had a nearly equal distribution regarding sex, age, and vaccine type. Finally, this study described the self-reported side effects of the general population using anonymous responses. These side effects could be confusing for individuals with no medical background. Moreover, the side effects were not verified or confirmed, nor were they officially recorded or documented; they could have been under- or over-described by the participants.

4.2. Strengths

To our knowledge, this study is one of the first studies in Algeria, the Middle East, and African countries that investigated the self-reported side effects of COVID-19 booster doses. Therefore, the results of this study could be very helpful in understanding the side effects of vaccines and, accordingly, contribute to the confirmation of the short-term safety of vaccines and to combatting the phenomenon of booster vaccine reluctance, especially in low- and middle-income countries.
5. Conclusions

Despite some limitations related to the nature and size of the sample, this study has confirmed the short-term safety of adenoviral-based and inactivated-virus booster doses used in Algeria. In fact, the side effects following such boosters—which included injection site pains and some systemic side effects, such as fever and fatigue—were mainly mild, of short duration, and less severe than those that followed the primer doses, except for individuals who received inactivated-virus or adenoviral-based vaccines for their primer-booster doses.

These safety results could be helpful for the public health authorities in their battle against vaccine hesitancy in general and, in particular, the new phenomenon of booster-dose hesitancy.

Author Contributions: Conceptualization, M.L.; methodology, M.L.; software, M.L.; validation, M.L.; formal analysis, M.L.; investigation, M.L.; resources, M.L.; data curation, M.L., H.A.A., S.A., M.A.R., S.B. and D.B.; writing—original draft preparation, M.L.; writing—review and editing, M.L. and H.A.A.; visualization, M.L., H.A.A., S.B. and D.B.; supervision, M.L.; project administration, M.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: This study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of The Faculty of Natural and Life Sciences, University of Djelfa (Reference:/04/2022).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Acknowledgments: The authors would like to thank all participants in this study.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Aouissi, H.A.; Kechebar, M.S.A.; Ababsa, M.; Roufayel, R.; Neji, B.; Petrisor, A.-I.; Hamimes, A.; Epelboin, L.; Ohmagari, N. The Importance of Behavioral and Native Factors on COVID-19 Infection and Severity: Insights from a Preliminary Cross-Sectional Study. Healthcare 2022, 10, 1341. [CrossRef] [PubMed]
2. World Health Organization (WHO). Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/ (accessed on 13 September 2022).
3. Aouissi, H.A.; Hamimes, A.; Ababsa, M.; Bianco, L.; Napoli, C.; Kebaili, F.K.; Kraulakis, A.E.; Bouzekri, H.; Dhama, K. Bayesian Modeling of COVID-19 to Classify the Infection and Death Rates in a Specific Duration: The Case of Algerian Provinces. Int. J. Environ. Res. Public Health 2022, 19, 9586. [CrossRef] [PubMed]
4. Alzarea, A.I.; Khan, Y.H.; Alatawi, A.D.; Alanazi, A.S.; Alzarea, S.I.; Butt, M.H.; Almalki, Z.S.; Alahmari, A.K.; Mallhi, T.H. Surveillance of Post-Vaccination Side Effects of COVID-19 Vaccines among Saudi Population: A Real-World Estimation of Safety Profile. Vaccines 2022, 10, 924. [CrossRef] [PubMed]
5. Hotez, P.J.; Batista, C.; Ben Amor, Y.; Ergonul, O.; Figueroa, J.P.; Gilbert, S.; Gursel, M.; Hassanain, M.; Kang, G.; Kaslow, D.C.; et al. Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic. EClinicalMedicine 2021, 39, 101053. [CrossRef]
6. World Health Organization (WHO). COVID-19 Vaccine Tracker and Landscape. 2022. Available online: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (accessed on 13 September 2022).
7. Kunal, S.; Sakthivel, P.; Gupta, N.; Ish, P. Mix and match COVID-19 vaccines: Potential benefit and perspective from India. Postgrad. Med. J. 2022, 98, e99–e101. [CrossRef]
8. Menni, C.; May, A.; Polidori, L.; Louca, P.; Wolf, J.; Capdevila, J.; Hu, C.; Ourselin, S.; Steves, C.J.; Valdes, A.M.; et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: A prospective community study from the ZOE COVID Study. Lancet Infect. Dis. 2022, 22, 1002–1010. [CrossRef]
9. Al-Hanawi, M.K.; Keetile, M.; Kadasah, N.A.; Alshareef, N.; Qattan, A.M.N.; Alshareqi, O. Side Effects and Perceptions of COVID-19 Vaccination in Saudi Arabia: A Cross-Sectional Study. Front. Med. 2022, 9, 899517. [CrossRef]
10. Riad, A.; Hocková, B.; Kantorová, L.; Slávík, R.; Špurná, L.; Stelb, A.; Havrilák, M.; Klugar, M. Side Effects of mRNA-Based COVID-19 Vaccine: NationwidePhase IV Study among Healthcare Workers in Slovakia. Pharmaceuticals 2021, 14, 873. [CrossRef]
11. Alshahrani, M.M.; Alqahtani, A. Side Effects of Mixing Vaccines against COVID-19 Infection among Saudi Population. *Vaccines* **2022**, *10*, 519. [CrossRef]

12. Orebi, H.A.; Emara, H.E.; Alhindi, A.A.; Shabin, M.R.; Hegazy, A.H.; Kabbash, I.A.; Saied, S.M. Perceptions and experiences of COVID-19 vaccines’ side effects among healthcare workers at an Egyptian University Hospital: A cross-sectional study. *Trop. Med. Health* **2022**, *50*, 37. [CrossRef]

13. Hatmal, M.M.; Al-Hatamleh, M.A.I.; Olaimat, A.N.; Mohamud, R.; Fawaz, M.; Kateeb, E.T.; Alkhairy, O.K.; Tayyem, R.; Lounis, M.; Al-Raei, M.; et al. Reported adverse effects and attitudes among Arab populations following COVID-19 vaccination: A large-scale multinational study implementing machine learning tools in predicting post-vaccination adverse effects based on predisposing factors. *Vaccines* **2022**, *10*, 366. [CrossRef] [PubMed]

14. Lounis, M.; Rais, M.A.; Bencherit, D.; Aouissi, H.A.; Klugarov, A.; Klugar, M.; Riad, A. Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers. *Front. Public Health* **2022**, *10*, 896343. [CrossRef] [PubMed]

15. Dziedzic, A.; Riad, A.; Attia, S.; Klugar, M.; Tanasiewicz, M. Self-Reported Adverse Events of COVID-19 Vaccines in Polish Healthcare Workers and Medical Students. Cross-Sectional Study and Pooled Analysis of CoVaST Project Results in Central Europe. *J. Clin. Med.* **2021**, *10*, 5338. [CrossRef] [PubMed]

16. Nguyen, D.C.; Dao, T.L.; Truong, T.M.D.; Nguyen, T.H.; Phan, T.N.; Nguyen, H.M.; Pham, T.D.; Nguyen, X.B.; Nguyen, T.B.; Hoang, V.T. Short-Term Adverse Effects Immediately after the Start of COVID-19 Booster Vaccination in Vietnam. *Vaccines* **2022**, *10*, 1325. [CrossRef] [PubMed]

17. Levin, E.G.; Lustig, Y.; Cohen, C.; Fluss, R.; Indenbaum, V.; Amit, S.; Doolman, R.; Asraf, K.; Mendelson, E.; Ziv, A.; et al. Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months. *N. Engl. J. Med.* **2021**, *385*, e84. [CrossRef]

18. Shekhar, R.; Garg, I.; Pal, S.; Kottewar, S.; Sheikh, A.B. COVID-19 vaccine booster: To boost or not to boost. *Infect. Dis. Rep.* **2021**, *13*, 924–929. [CrossRef]

19. Tang, P.; Hasan, M.R.; Chemaitelly, H.; Yassine, H.M.; Benslimane, F.M.; Al Khatib, H.A.; AlMukdad, S.; Coyle, P.; Ayoub, H.H.; Al Kanaani, Z.; et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. *Nat. Med.* **2021**, *27*, 2136–2143. [CrossRef]

20. Rzymski, P.; Sikora, D.; Zeyland, J.; Poniedziałek, B.; Kiedik, D.; Falfushynska, H.; Fal, A. Frequency and Nuisance Level of Adverse Events in Individuals Receiving Homologous and Heterologous COVID-19 Booster Vaccine. *Vaccines* **2022**, *10*, 754. [CrossRef]

21. Pugliese, M.E.; Battaglia, R.; Raso, M.G.; Chiaraavalloti, R.; Coschignano, F.; Pagliuso, A.; Bruschetta, R.; Pugliese, G.; Scola, P.; Tonin, P.; et al. Heterologous COVID-19 Booster Vaccination in the Chronic Disorder of Consciousness: A Pilot Study. *Clin. Pract.* **2022**, *12*, 318–325. [CrossRef]

22. Munro, A.P.S.; Janani, L.; Cornelius, V.; Aley, P.K.; Babbage, G.; Baxter, D.; Bula, M.; Cathie, K.; Chatterjee, K.; Dodd, K.; et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCoV-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial. *Lancet* **2021**, *398*, 2258–2276. [CrossRef]

23. Saltoglu, N.; Dinç, H.; Balkan, I.J.; Can, G.; Özbey, D.; Beytur, A.N.; Keskin, E.; Budak, B.; Aydoğan, O.; Mente, B.; et al. Heterologous booster COVID-19 vaccine elicited potent immune responses in HCWs. *Diagn. Microbiol. Infect. Dis.* **2022**, *104*, 115758. [CrossRef] [PubMed]

24. Liang, X.M.; Xu, Q.Y.; Jia, Z.J.; Wu, M.J.; Liu, Y.Y.; Lin, L.R.; Liu, L.L.; Yang, T.C. A Third Dose of an Inactivated Vaccine Dramatically Increased the Levels and Decay Times of Anti-SARS-CoV-2 Antibodies, but Disappointingly Declined Again: A Prospective, Longitudinal, Cohort Study at 18 Serial Time Points Over 368 Days. *Front. Immunol.* **2022**, *13*, 876037. [CrossRef] [PubMed]

25. Ourworlindata. 2022. Available online: https://ourworldindata.org/covid-vaccinations (accessed on 13 September 2022).

26. Lounis, M.; Bencherit, D.; Rais, M.A.; Riad, A. COVID-19 Vaccine Booster Hesitancy (VBH) and Its Drivers in Algeria: National Cross-Sectional Survey-Based Study. *Vaccines* **2022**, *10*, 621. [CrossRef] [PubMed]

27. Ourworlindata. Coronavirus (COVID-19) Vaccinations. 2022. Available online: https://ourworldindata.org/grapher/cumulative-covid-vaccine-boosterdoses?country=AT&\7\7IDZA (accessed on 13 September 2022).

28. Del Águila, M.R.; Gonzalez-Ramirez, A.R. Sample size calculation. *Allergol. Immunopathol.* **2014**, *42*, 485–492. [CrossRef] [PubMed]

29. Lounis, M.; Abdelhadi, S.; Rais, M.A.; Bencherit, D.; Sallam, M. Intention to get COVID-19 vaccination and its associated predictors: A cross-sectional study among the general public in Algeria. *Vacunas* **2022**, *23*, S52–S59. [CrossRef] [PubMed]

30. Lazarus, J.V.; Wyka, K.; White, T.M.; Piccio, C.A.; Rabin, K.; Ratzan, S.C.; Leigh, J.P.; Hu, J.; El-Mohandes, A. Revisiting COVID-19 vaccine hesitancy around the world using data from 23 countries in 2021. *Nat. Commun.* **2022**, *13*, 3801. [CrossRef]

31. Klugar, M.; Riad, A.; Mohanan, L.; Pokorná, A. COVID-19 Vaccine Booster Hesitancy (VBH) of Healthcare Workers in Czechia: National Cross-Sectional Study. *Vaccines* **2021**, *9*, 1437. [CrossRef]

32. Chansaenroj, J.; Suntrongwong, N.; Kanokudom, S.; Assawakosri, S.; Yorsaeng, R.; Klinfueng, S.; Wongrisang, L.; Srimuan, D.; Thatsanatorn, T.; et al. Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine. *Vaccines* **2022**, *10*, 1071. [CrossRef]
33. Lin, Z.; Cheng, M.; Zhu, F.; Yang, X.; Zuo, J.; He, S. Immunogenicity and safety of different platforms of COVID-19 vaccines given as a third (booster) dose in healthy adults. *J. Med. Virol.* **2022**, *94*, 4047. [CrossRef]

34. Alrudian, N.; Mokhatrish, M.; Alghuwanem, M.A.; Alhaddad, A.T.; Alanazi, S.S.; Altamimi, M.A.; Alahmadi, L.M.; Alenezi, A.K.; Ali, A.H.A. Side effects of COVID-19 third booster dose among healthcare workers in Saudi Arabia. *Med. Sci.* **2022**, *9*, 33. [CrossRef]

35. Ali, M.D.; Almadan, L.Z.; Alghamdi, R.A.; Alghamdi, A.S.; Almarhoon, S.A.; Hassan, Y.A.; Ahmad, A.; Gho, S.A.; Banu, N.; Elrafi, Z. Evaluation of Prevalence of Side-Effects Associated with Booster Dose of mRNA-Based COVID-19 Vaccine Among Healthcare Workers in Eastern Province, Saudi Arabia: A Descriptive Cross-Sectional Study. *Infect. Drug Resist.* **2022**, *15*, 4335. [CrossRef] [PubMed]

36. El-Shitany, N.A.; Bagher, A.M.; Binmahfouz, L.S.; Eid, B.G.; Almukadi, H.; Badr-Eldin, S.M.; El-Hamamsy, M.; Mohammedsaleh, Z.M.; Saleh, F.M.; Almuhayawi, M.S.; et al. The Adverse Reactions of Pfizer BioNTech COVID-19 Vaccine Booster Dose are Mild and Similar to the Second Dose Responses: A Retrospective Cross-Sectional Study. *Infect. Drug Resist.* **2022**, *15*, 6821–6836. [CrossRef] [PubMed]

37. Matula, Z.; Gönzi, M.; Beko, G.; Kádár, B.; Ajzner, É.; Uher, F.; Vályi-Nagy, I. Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy. *Vaccines* **2022**, *10*, 539. [CrossRef] [PubMed]

38. Hause, A.M. Safety Monitoring of an Additional Dose of COVID-19 Vaccine—United States, 12 August–19 September 2021. *Morb. Mortal. Wkly. Rep.* **2021**, 70, 1379. [CrossRef]

39. Hause, A.M. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12–17 Years—United States, 9 December 2021–20 February 2022. *Morb. Mortal. Wkly. Rep.* **2022**, *71*, 347. [CrossRef]

40. Hause, A.M.; Baggs, J.; Marquez, P.; Myers, T.R.; Su, J.R.; Blanc, P.G.; Baumblatt, J.A.G.; Woo, E.J.; Gee, J.; Shimabukuro, T.T.; et al. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults—United States, 22 September 2021–6 February 2022. *Morb. Mortal. Wkly. Rep.* **2022**, *71*, 249–254. [CrossRef]

41. Folegatti, P.M.; Ewer, K.J.; Aley, P.K.; Angus, B.; Belij-Rammerstorfer, S.; Bellamy, D.; Bibi, S.; Bittaye, M.; Clutterbuck, E.A.; et al. Safety and Immunogenicity of the ChAdOx1 NCoV-19 Vaccine against SARS-CoV-2: A Preliminary Report of a Phase I/2, Single-Blind, Randomised Controlled Trial. *Lancet* **2020**, *396*, 467–478. [CrossRef]

42. Doedée, A.M.C.M.; Boland, G.J.; Pennings, J.L.; De Klerk, A.; Berbers, G.A.M.; Van Der Klis, F.R.M.; De Melker, H.E.; Van Loveren, H.; Janssen, R. Effects of Prophylactic and Therapeutic Paracetamol Treatment during Vaccination on Hepatitis B Antibody Levels in Adults: Two Open-Label, Randomized Controlled Trials. *PLoS ONE* **2014**, *9*, e98175. [CrossRef]

43. Coronavirus (COVID-19) Vaccines Side Effects and Safety. Available online: https://www.nhs.uk/conditions/coronavirus-COVID-19/coronavirus-vaccination/safety-and-side-effects/ (accessed on 13 September 2022).

44. Flanagan, K.L.; Fink, A.L.; Plebanski, M.; Klein, S.I. Sex and Gender Differences in the Outcomes of Vaccination over the Life Course. *Annu. Rev. Cell Dev. Biol.* **2017**, *33*, 577–599. [CrossRef]

45. Nohl, A.; Brune, B.; Weichert, V.; Standl, F.; Stang, A.; Dudda, M. COVID-19: Vaccination Side Effects and Sick Leave in Frontline Healthcare-Workers—A Web-Based Survey in Germany. *Vaccines* **2022**, *10*, 411. [CrossRef]

46. Aouissi, H.A.; Bollauchet, I. What about Rheumatic Diseases and COVID-19? *New Microbes New Infect.* **2021**, *41*, 100846. [CrossRef] [PubMed]

47. De Sarro, C.; Papadopoli, R.; Morgante, M.C.; Nobile, C.G.A.; De Sarro, G.; Pileggi, C. Vaccinations Status against Vaccine-Preventable Diseases and Willingness to Be Vaccinated in an Italian Sample of Frail Subjects. *Vaccines* **2022**, *10*, 1311. [CrossRef] [PubMed]

48. Igucel, I.; Maldonado, A.L.; Ruiz-Cabello, A.L.; Casaus, M.; Moreno, L.A.; Martinez-Jarreta, B. Association between COVID-19 Vaccine Side Effects and Body Mass Index in Spain. *Vaccines* **2021**, *9*, 1321. [CrossRef] [PubMed]